Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience

被引：0
|
作者：
Ghamsari, Farid [1 ]
Trando, Aaron [2 ]
Medley, Katherine [3 ]
Martino, Janine [3 ]
Block, Shanna [3 ]
Wells, Kaitlyn [3 ]
Doan, Thu [3 ]
Quach, Anthony [3 ]
Cheng, Renee [4 ]
Costello, Caitlin [1 ]
Jeong, Autumn [5 ]
Saunders, Ila [6 ]
机构：
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] UCSD Sch Med, San Diego, CA USA
[3] UCSD Hlth, Dept Pharm, San Diego, CA USA
[4] UCSD Hematol Oncol Fellowship Program, San Diego, CA USA
[5] UCSD Div Blood & Bone Marrow Transplantat, San Diego, CA USA
[6] UCSD Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-025
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [41] Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma.
    Becnel, Melody
    Ferreri, Christopher J.
    Feng, Lei
    Richards, Tiffany Ann
    Horowitz, Sandra B.
    Patel, Nimisha
    Gombos, Dan S.
    Razmandi, Azadeh
    Murga, Astrid
    Seif, Sherif
    Youssef, George
    Murphy, Kevin
    Kaufman, Gregory Peter
    Weber, Donna M.
    Patel, Krina K.
    Thomas, Sheeba K.
    Manasanch, Elisabet Esteve
    Orlowski, Robert Z.
    Lee, Hans C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-Class Relapsed/Refractory Multiple Myeloma (RRMM): A Single-Institution Experience
    Pennipede, Dante
    Mohyuddin, Ghulam Rehman
    Hawkins, Ryan
    Ganguly, Siddhartha
    Shune, Leyla
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S434 - S435
  • [43] Predictive factors for outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience
    Khan, Abdullah
    Faisal, Muhammad
    Zhao, Qiuhong
    Ozga, Michael
    Bumma, Naresh
    Cottini, Francesca
    Devarakonda, Srinivas
    Rosko, Ashley
    Umyarova, Elvira
    Benson, Don
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S173 - S174
  • [44] Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad Z.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (06)
  • [45] Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
    Dileo, Rachel
    Mewawalla, Prerna
    Patrus, Gina
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2024, 144 : 4742 - 4743
  • [46] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    BLOOD, 2018, 132
  • [47] Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
    Mark, Tomer
    Falkenstein, Angelica
    Kish, Jonathan
    FUTURE ONCOLOGY, 2022, 18 (05) : 553 - 564
  • [48] Real-World Outcomes for Standard-ofCare Treatments in Patients with Relapsed/Refractory Multiple Myeloma
    Delforge, Michael
    Vekemans, Marie-Christiane
    Anguille, Sebastien
    Depaus, Julien
    Meuleman, Nathalie
    Van de Velde, Ann
    Van de Broek, Isabelle
    Strens, Danielle
    Van Hoorenbeeck, Sandra
    Moorkens, Evelien J.
    Diels, Jorks
    Ghilotti, Francesca
    Dalhuisen, Sander
    Vandervennet, Sophie
    BLOOD, 2021, 138
  • [49] Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma (RRMM): A Real-World Analysis
    Dong, Sharlene
    Banerjee, Rahul
    Khan, Adeel
    Wang, Mengru
    Wang, Xiaoliang
    Afghahi, Anosheh
    Afrough, Aimaz
    Janakiram, Murali
    Wang, Bo
    Cowan, Andrew
    Sperling, Adam
    Anderson, Larry
    Rajkumar, S. Vincent
    Kaur, Gurbakhash
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S258 - S259
  • [50] Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma
    Jandial, Aditya
    Mishra, Kundan
    Lad, Deepesh
    Prakash, Gaurav
    Khadwal, Alka
    Malhotra, Pankaj
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1102 - 1104
12345